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Abstract
Introduction: The influence of demographic and clinical factors on the outcome
of  131I therapy in hyperthyroid patients has been examined, based on 
a retrospective evaluation of results obtained in patients submitted to 131I
treatment at the Department of Nuclear Medicine and Oncological Endocrinology,
Medical University of Lodz (Province Hospital, Zgierz). The goal of the study was
to analyse such factors as the age and sex of patients, disease duration, as well
as the hormonal status before 131I application, which could have an influence
on the effects of therapy with radioiodine 131I.
Material and methods: The study involved 500 randomly selected patients with
hyperthyroidism, treated with 131I radioiodine. The following 3 groups were
defined: group 1 – patients with multinodular goitre (MNG), n = 200; group 2 
– patients with a single autonomous nodule of the thyroid (AFTN), n = 100; 
group 3 – patients with Graves’ disease (GD), n = 200. The local ethics committee
(in the Polish Mother’s Memorial Hospital – Research Institute, Lodz) approved
the study.
Results: The obtained results indicate that the efficacy of therapy with 131I applied
in patients with MNG, AFTN and GD does not depend on either patient sex or
patient age. The length of antithyroid treatment before 131I therapy onset does
not appear to have any effect on the therapy outcome, and the baseline
thyrotropin concentration seems to be significant only in the case of GD. 
Conclusions: The analysed demographic factors do not affect the outcome of 131I
therapy in hyperthyroidism.
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Introduction
The treatment of hyperthyroidism with radioiodine is an approved and
commonly practised therapeutic method, especially in cases of Graves’
disease and single toxic adenomas. Since complete cure, following a single
therapeutic dose of radioiodine, is not observed in all the treated patients,
while hypothyroidism is observed in others, an evaluation has for some
years been attempted, trying to identify what factors affect the outcome
of 131I therapy. Also new methods have been sought to improve the to-
date results of this therapy.
The goal of the study was to analyse demographic and clinical factors
affecting the outcome of treatment with radioiodine in hyperthyroid patients. 
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Material and methods
The study involved 500 randomly selected
patients with hyperthyroidism, treated with 131I
radioiodine at the Department of Nuclear Medicine
and Oncological Endocrinology in Zgierz. The local
ethics committee (in the Polish Mother’s Memorial
Hospital – Research Institute, Lodz) approved the
study.
In the analysed group of 500 patients, the
following 3 groups were defined: group 1 – patients
with multinodular goitre (MNG), n = 200; group 2 
– patients with a single autonomous nodule of the
thyroid (autonomously functioning thyroid nodule
– AFTN), n = 100; group 3 – patients with Graves’
disease (GD), n = 200.
The patients were assigned to particular groups,
following clinical examination, hormonal and
immunological tests, sonographic imaging of the
thyroid gland and thyroid scintigraphy. 
In the studied population, the effects of
demographic data, such as the age and sex of
patients, and disease duration (in categories:
below/above 3 months, below/above 3 years), were
analysed, separately for each disease entity, as well
as the hormonal status before 131I application. 
The group of patients with multinodular goitre
consisted of 171 females (85.5%) aged 34-81 years
(mean age: 60.7 years) and 29 males (14.5%) aged
45-79 years (mean age: 61.7 years). The group of
patients with a single autonomous nodule
consisted of 88 females (88%) aged 32-79 years
(mean age: 60.4 years) and 12 males (12%) aged
36-70 years (mean age: 55 years). The group of
patients with Graves’ disease consisted of 151
females (78.5%) aged 24-81 years (mean age: 48.4
years) and 43 males (21.5%) aged 31-77 years (mean
age: 52.9 years). 
Prior to radioiodine administration, the hormonal
status was evaluated in the patients, based on
serum concentrations of free thyroxine (FT4), free
triiodothyronine (FT3) and thyrotropin (TSH). In each
of the above-mentioned 3 groups, the following
subgroups were identified:
A) patients with hormonal euthyroidism after
administration of antithyroid drugs (methimazole
or propylthiouracil),
B) patients with TSH suppression (< 0.3 µIU/ml) and
normal FT4 and FT3 values,
C) patients with TSH suppression and elevated
values of FT4 and/or FT3.
In group 1 (with multinodular goitre), 80 patients
(40%) revealed euthyroidism (subgroup A), 
40 patients (20%) demonstrated subclinical
hyperthyroidism (subgroup B) and 80 patients (40%)
were hyperthyroid (subgroup C). In group 2 (with 
a single autonomous nodule), 12 patients (12%)
revealed euthyroidism, 31 patients (31%)
demonstrated subclinical hyperthyroidism and 
57 patients (56%) were hyperthyroid. In group 3
(with Graves’ disease), 60 patients (30%) revealed
euthyroidism, 52 patients (26%) demonstrated
subclinical hyperthyroidism and 88 patients (44%)
were hyperthyroid. 
Regarding the duration of treatment with
antithyroid drugs before 131I therapy, 77 patients
in group 1 (38.5%) were treated for less than 
3 months, 118 patients (59%) for 3 months to 3 years,
and 5 patients (2.5%) for more than 3 years. In
group 3, 50 patients (25%) were treated for less
than 3 months, 131 patients (65.5%) for 3 months
to 3 years and 19 patients (9.5%) for more than 
3 years. The patients with a single autonomous
nodule (group 2) received 131I without prior
treatment with antithyroid medications.
131I radioiodine was administered during
patients’ hospitalisation. The administered doses
(calculated according to the formula proposed by
Marinelli et al. [1]) were within the range of dose
values used in hyperthyroidism:
• group 1 – MNG – from 236.8 MBq (6.4 mCi) to
1498.5 MBq (40.5 mCi),
• group 2 – AFTN – from 236.8 MBq (6.4 mCi) to
1217.3 MBq (32.9 mCi),
• group 3 – GD – from 111 MBq (3 mCi) to 1198.8
MBq (32.5 mCi).
The effect of radioiodine therapy was evaluated
after 6 months on the basis of clinical examination
and TSH and thyroid hormone concentrations. The
results of treatment were assigned to 2 subgroups
in each of the study group – MNG, AFTN and GD:
• effective therapy – euthyroidism or hypo  thy  -
roidism,
• ineffective therapy – persistent hyperthyroidism.
Additionally, it should be mentioned that the
cases of subclinical hyperthyroidism were con  -
sidered as ineffective treatment, while the cases of
subclinical hypothyroidism were included in the
group of effective therapy.
The concentrations of FT3 (pg/ml) and FT4 in
blood serum (pmol/l) were measured by the
radioimmunometric method with standard,
commercially available kits (Brahms), and TSH
(µIU/ml) concentrations were measured by the IRMA
radioimmunometric method, using a standard,
commercially available kit for TSH assay (Brahms). 
The concentrations of anti-TPO antibodies
(IU/ml) were measured by the RAI immunometric
method, using a commercially available anti-TPO
test (Brahms), and the concentrations of anti-TSH
receptor antibodies were measured by the
radioreceptor method (TRAK human kits, Brahms). 
Results
In 133 patients (26.6%) – out of 500 – the 131I
therapy was ineffective, i.e., clinical and biochemical
hyperthyroidism was further maintained. In Arch Med Sci 4, August / 2010 613
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367 patients (73.4%), either euthyroidism or
hypothyroidism was obtained.
The following results were obtained in particular
groups: in group 1 (multinodular goitre): 25% –
ineffective therapy, 75% – effective therapy (19% –
hypothyroidism, 56% – euthyroidism); in group 2
(single autonomous nodule): 18% – ineffective
therapy, 82% – effective therapy (9% – hypo  -
thyroidism, 73% – euthyroidism); in group 3 (Graves’
disease): 32.5% – ineffective therapy, 67.5% –
effective therapy (27.5% – euthyroidism, 40% –
hypothyroidism). 
Analysis of demographic data
While analysing demographic data, such as the
age and sex of the patients, it was found that all
the studied groups were uniform, regarding sex and
age distribution in the subgroups of therapy
effectiveness. 
The mean age of the patients was as follows:
• group 1: 61.7 ±11.23 years (x ± SD), including the
particular subgroups of therapy effectiveness
(hyperthyroidism – HYPER, euthyroidism – EU,
hypothyroidism – HYPO): {0 – HYPER} – 60.3
±11.21; {1 – EU} – 61.4 ±10.13 and {2 – HYPO} – 61.2
±10.15;
• group 2: 60.4 ±11.35, including the particular
subgroups of therapy effectiveness: {0 – HYPER}
– 62.8 ±9.36; {1 – EU} – 59.2 ±11.15 and {2 – HYPO}
– 63.2 ±10.35;
• group 3: 49.5 ±11.16, including the particular
subgroups of therapy effectiveness: {0 – HYPER}
– 48.5 ±10.42; {1 – EU} – 52.6 ±11.22 and 
{2 – HYPO} – 49.3 ±11.10.
No statistically significant differences in the
mean age of patients in various groups of
therapeutic effectiveness were observed in any of
the study groups (the level of significance of the
variance analysis test was always considerably
higher than 0.05). Analysing sex distribution among
the patients in particular therapeutic groups, no
statistically significant correlations were found
between sex and the effectiveness of 131I treatment.
Nor was there statistically significant dependence
of the treatment outcome on patient sex in any of
the study groups. Contingency tables and related
Pearson’s χ2 test were applied for verification of the
above phenomenon. 
As presented above in Tables I-III, Pearson’s χ2
test and Spearman’s rank correlation coefficients,
the latter calculated for evaluation of correlations,
were statistically insignificant. 
Analysis of clinical data
Analysing the importance of the baseline
hormonal status (before 131I radioiodine application)
on the outcome of radioiodine therapy, the following
criteria were accepted: “0” – hyperthyroidism (TSH
suppression and elevated thyroid hormones), “1” –
subclinical hyperthyroidism (TSH suppression and
normal thyroid hormones), “2” – euthyroidism
(normal TSH and thyroid hormone concentrations),
comparing the criteria with the therapeutic
outcome (Table IV–VI).
Sex Effectiveness of 131I treatment Statistical
01 T ogether
analysis
F 41 130 171 χ2 = 0.7, p = 0.4
M 9 20 29 rs = –0.06, p = 0.4
F + M 50 150 200
Table I. Analysis of treatment effectiveness in MNG
group
Sex Effectiveness of 131I treatment Statistical
01 T ogether
analysis
F1 7 7 1 8 8 χ2 = 0.3, p = 0.6
M 1 11 12 rs = 0.09, p = 0.3
F + M 18 82 100
Table II. Analysis of treatment effectiveness in AFTN
group 
Sex Effectiveness of 131I treatment Statistical
01 T ogether
analysis
F 49 108 157 χ2 = 0.6, p = 0.5
M1 6 2 74 3 rs = –0.05, p = 0.4
F + M 65 135 200
Table III. Analysis of treatment effectiveness in GD
group 
Sex           Effectiveness of 131I treatment Statistical
01 T ogether
analysis
02 1 5 9 8 0 χ2 = 4.4, p = 0.1
11 4 2 5 3 9 rs = 0.08, p = 0.2
21 5 6 6 8 1
Together 50 150 200
Table IV. Correlation between the effectiveness of 131I
treatment and hormonal status of MNG patients 
Hormonal Effectiveness of 131I treatment Statistical
status
01 T ogether analysis
01 0 4 7 5 7 χ2 = 0.5, p = 0.7
1 5 26 31 rs = 0.03, p = 0.7
23 9 1 2
Together 18 82 100
Table V. Correlation between the effectiveness of 131I
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The results presented above suggest that only
in patients of the GD group did the baseline
concentrations of TSH and thyroid hormones 
(p < 0.05) demonstrate some influence on the
outcome of radioiodine therapy (Table VI), i.e., the
appropriate preparation of patients with antithyroid
drugs for 131I treatment seems to be important to
obtain, at least, normal levels of FT3 and FT4
hormones. 
The duration of disease is another variable
which may have affected therapy outcome in the
groups with multinodular goitre and Graves’
disease; it was divided into the following 
3 categories: “0” – up to 3 months, “1” – from 
3 months to 3 years, and “2” – above 3 years
(Tables VII, VIII).
As presented above, the obtained values of
Pearson’s  χ2 test, calculated for the contingency
tables, turned out to be statistically insignificant,
similarly as Spearman’s rank correlation coefficients
(Tables VII, VIII). 
Discussion
The above results demonstrate that the efficacy
of therapy with 131I applied in patients with MNG,
AFTN and GD does not depend on either patient
sex or patient age. The length of antithyroid
treatment before 131I therapy onset does not appear
to have any effect on the therapy outcome, and the
baseline TSH concentration seems to be significant
only in the case of GD. 
131I therapy is a non-invasive and safe method,
used already for more than 50 years, and the
primary therapeutic protocol – besides antithyroid
drugs and surgery – recommended in hyper  -
thyroidism [2-4]. However, the planned therapeutic
effects are not obtained in all patients, so studies
have been performed for years to identify new
methods improving the to-date therapeutic
outcomes. 
The goal of the study was to search for and
analyse factors which could have any influence on
the effects of therapy with 131I. The effects of
radioiodine treatment, unlike those of surgical
intervention, are extended in time, while the rate
of their occurrence depends on the therapeutic
dose of 131I. The majority of authors report that the
period of 6 months after radioiodine administration
is sufficient to stabilise thyroid functions [5-7].
Therefore, the effects of radioiodine therapy, applied
to 500 hyperthyroid patients, were summarised in
our study also after 6 months. After the mentioned
period, persistent hyperthyroidism was found in
27% of patients, euthyroidism in 48%, and
hypothyroidism in 25% (in other words, the therapy
was effective in 73%), using doses from 129 MBq
to 1665 MBq, with a mean dose of 740 MBq 
(3.5 mCi to 45 mCi, mean dose of approximately 
20 mCi). In practice, the relatively high percent of
hypothyroidism after 131I therapy is still a problem.
However, it is now regarded as a complication of
the applied therapy. The percent of persistent
hyperthyroidism after radioiodine therapy is
different in particular disease entities. The French
authors [8] who performed a retrospective
evaluation of 100 patients with Graves’ disease,
following radioiodine therapy, found hypothyroidism
in 33% of the treated patients after 6-9 months. In
German centres [5, 9, 10] hypothyroidism was found
in 30-46% of patients with Graves’ disease and in
8-28% of patients with nodular goitre. An Italian
group [11] evaluated the incidence of hypo  -
thyroidism at as much as 74% in Graves’ disease
already after 3 months, while no hypo  thyroidism
was observed by the authors in nodular goitre after
that period. After one year from the performed 131I
therapy, only 3% of the patients revealed
hypothyroidism (the observation included 146
patients with Plummer’s disease). 
Hormonal Effectiveness of 131I treatment Statistical
status 01 T ogether analysis
03 1 5 7 8 8 χ2 = 6.2, p < 0.05
12 2 3 1 5 3 rs = 0.11, p = 0.1
21 2 4 7 5 9
Together 65 135 200
Table VI. Correlation between the effectiveness of
131I treatment and hormonal status of GD patients 
Duration Effectiveness of 131I treatment Statistical
01 T ogether
analysis
01 8 5 9 7 7 χ2 = 0.3, p = 0.8
1 31 87 118 rs = –0.03, p = 0.7
21 4 5
Together 50 150 200
Table VII. Correlation between the effectiveness of
131I treatment and duration of antithyroid drug
therapy in MNG group
Duration Effectiveness of 131I treatment Statistical
01 T ogether
analysis
01 1 3 9 5 0 χ2 = 4.3, p = 0.1
1 49 82 131 rs = –0.09, p = 0.2
2 5 14 19
Together 65 135 200
Table VIII. Correlation between the effectiveness of
131I treatment and duration of antithyroid drug
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Vijayakumar et al. [12] reported, in a group of
147 GD patients, 57% cases of hypothyroidism 
5 months after 131I treatment. Ronga et al. [13]
reported 2.6% cases of hypothyroidism after many-
year observation of 1361 patients (82.4% with AFTN
and 17.6% with MNG). 
In our study, hypothyroidism occurred in 19% of
the patients with MNG, in 9% of patients in the
group with AFTN, and in 40% of the patients with
GD, which is not different from other results of
Polish authors [14, 15].
The persistent hyperthyroidism after 131I therapy
is still a therapeutic problem. The patients in whom
no therapeutic effect is achieved need subsequent
radioiodine doses to be administered, which, in
effect, leads to 100% cure of hyperthyroidism, but
in the majority of these patients, hypothyroidism
is the resulting adverse effect. As in the case of
persistent hypothyroidism, the percentage of
persistent hyperthyroidism is higher in GD than in
MNG or AFTN and amounts in our material to
32.5%, 25% and 9%, respectively. These results are
also similar to the data reported by the earlier
mentioned authors. 
In our study, the influence of patient sex and
age on the therapeutic outcome was evaluated. No
statistically significant differences were found in
the mean age of the patients in particular
subgroups of therapy efficacy. Nor was any
correlation found between patient sex and the
outcome of the therapy. 
Similarly, other authors did not observe any
effect of these parameters on the therapeutic
efficacy of 131I treatment [14, 16-19]. In turn,
Allahabadia et al. [20] observed, after 6 months,
a higher percentage of effective therapy in women
than in men (76.7% vs. 67.6%), as well as better
results in patients above 40 years old, when
compared with other patients below 40 (79.3% vs.
68.9%), although it is assumed that the thyroid
gland of younger persons is more susceptible to
irradiation. Consistently with the above,
Vijayakumar  et al. [12] reported a better
effectiveness of 131I treatment in women than in
men (62% vs. 46%, respectively). 
The effect of the hormonal status before 131I
administration on the therapy outcome was also
analysed, revealing a correlation between TSH and
therapy efficacy only in group 3 (GD). These results
may suggest that patients with GD should be
appropriately pre-treated with antithyroid
preparations in order to compensate the
biochemical hyperthyroidism, keeping in mind the
necessity of drug withdrawal at a proper time point
before radioiodine administration. 
Sabri et al. [21] also pointed attention to the fact
that in autoimmunological hyperthyroidism, the
lower is the baseline TSH concentration, the worse
is the efficacy of radioiodine treatment. Urbanek et
al. [17] believe, based on their evaluations, that both
thyroid hormone and TSH concentrations do not
allow for any prognosis of 131I therapy effects. 
In the medical literature, it is quite often
discussed how many days before 131I application
antithyroid drugs should be withdrawn [22]. Sabri et
al. [7] claim that conservative treatment should be
withdrawn a minimum one day before radioiodine
therapy; Urbanek et al. [17], Lind [23], and Kobe 
et al. [24] report that 2 days are enough; Andrade
et al. [25] propose 4 days, and Braga et al. [26] suggest
at least 6 days. Ronga et al. [13], following 40 years
of their experience, suggest the withdrawal of
antithyroid treatment in MNG 30 days before
radioiodine application. It is to be stressed here that
the majority of reports deal with the exact time of
antithyroid drug withdrawal before 131I treatment
application rather than with the total period of
administration of the drugs in question.
In most of the examined patients presented in
this report, antithyroid drugs were withdrawn within
3 days to 3 weeks before 131I administration (the
patients came from various centres in which they
were conservatively treated). Only 19 patients – out
of 500 patients treated with radioiodine – received 
a single dose of methimazole and in 14 (73.7%)
persistent hyperthyroidism was found. However, these
results do not allow for any conclusions that
methimazole influences the efficacy of 131I therapy
because that group was very small and not
homogeneous with regards to the other variables. 
In our study, the duration of disease (more
precisely the duration of administration of
antithyroid drugs) exerted no effect on the final
effectiveness of treatment. In the analysed material,
the values of Pearson’s  χ2 test were statistically
insignificant, similarly as Spearman’s rank
correlation coefficients. 
The most important observation resulting from
the presented study is much better effectiveness
of 131I therapy in those GD patients who were –
prior to therapy – successfully pre-treated with
antithyroid drugs, with subsequent complete
normalisation of thyroid hormone concentrations. 
In conclusion, our results indicate that the
effectiveness of therapy with 131I in patients with
MNG, AFTN and GD does not depend on either
patient sex or patient age. The length of antithyroid
treatment before 131I therapy onset does not appear
to have any effect on the therapy outcome.
Correlation between TSH concentration before 131I
administration and therapy efficacy has been
documented only in GD group.
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